Videos

In this segment of her EADV interview, Markowitz highlights 3-D imaging data from the DISCOVER study on dupilumab (Dupixent) and atopic dermatitis in skin of color.

Radhakrishnan emphasizes the importance of individualized IgAN care and how to best use currently available and emerging treatments.

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.

This interview from EADV highlights recent data from PRIME and PRIME2 on the effects of dupilumab (Dupixent) on itch and pain in prurigo nodularis.

In this interview, additional information on roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis was highlighted.

A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.

Peters emphasized how the new findings reinforce treatment strategies for chronic rhinosinusitis with nasal polyps.

Radhakrishnan breaks down the recent KDIGO IgAN guidelines and describes the evolving therapeutic landscape of IgA nephropathy.

This interview follows the FDA’s recent approval of Arcutis's roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from EADV.

Staller describes key takeaways from the 12 conditional recommendations made in the American Gastroenterological Association’s new gastroparesis guideline.

This interview highlights the significance of remibrutinib's recent FDA approval for clinicians treating chronic spontaneous urticaria.

Hanania discussed the rationale and findings of the BOREAS and NOTUS studies.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

This Savvy Stories episode of the Skin of Color Savvy podcast features 4 speakers highlighting the SOCS Clinical Investigators Training Program.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

In this interview at EADV, Bernstein highlights dupilumab’s impact on urticaria activity in individuals with chronic spontaneous urticaria (CSU).

If this connection is proven, the gut microbiome may present an entirely new pathway for treatment and prevention of heart failure.

This discussion highlights 24-week findings on povorcitinib for those with moderate to severe hidradenitis suppurativa (HS).

Rubin reflects on the FDA approval of a SC induction regimen for guselkumab (Tremfya) in UC and explains the significance of having both IV and SC induction options in IBD.

This EADV 2025 interview featuring Linda Stein Gold, MD, highlights her team’s findings on icotrokinra versus placebo and versus deucravacitinib in psoriasis.

A trio of experts and a patient advocate discuss unmet needs and recent innovations in kidney transplantation, from xenotransplantation to continuous hypothermic machine perfusion.

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

Neuen describes varying treatment effects with 4 different classes of IgAN therapeutics and future opportunities for personalized treatment.

This episode highlights the results of the ATTAIN-1 and STEP UP clinical trials, examining the potential of their respective GLP-1 RA subjects.

This interview highlighted findings on actinic keratosis following treatment with tirbanibulin.

Staller describes unmet needs in gastroparesis and key recommendations for its diagnosis and management from the new AGA guidelines.